Turning anemones into coral, and the future of psychiatric drugs
Why scientists are trying to make anemones act like corals, and why it’s so hard to make pharmaceuticals for brain diseases
First up on this week’s show, coaxing anemones to make rocks. Newsletter Editor Christie Wilcox joins host Sarah Crespi to discuss the difficulties of raising coral in the lab and a research group that’s instead trying to pin down the process of biomineralization by inserting coral genes into easy-to-maintain anemones.
Next on the show, a look at why therapeutics for both neurodegenerative disease and psychiatric illness are lagging behind other kinds of medicines. Steve Hyman, director of the Stanley Center for Psychiatric Research at the Broad Institute, talks with Sarah about some of the stumbling blocks to developing drugs for the brain—including a lack of diverse genome sequences—and what researchers are doing to get things back on track.
Finally, in a sponsored segment from the Science/AAAS Custom Publishing Office, associate editor Jackie Oberst discusses with Thomas Fuchs, dean of artificial intelligence (AI) and human health and professor of computational pathology and computer science at the Icahn School of Medicine at Mount Sinai, the potential and evolving role of AI in health care. This segment is sponsored by the Icahn School of Medicine at Mount Sinai.
This week’s episode was produced with help from Podigy.
Authors: Christie Wilcox; Sarah Crespi
Episode page: https://www.science.org/doi/10.1126/science.adm6756